NIPH Clinical Trials Search

Basic Information

Recruitment status	completed
Health condition(s) or Problem(s) studied
Date of first enrollment	23/09/2020
Target sample size	888
Countries of recruitment	Asia except Japan,North America,South America,Europe,Oceania,Japan
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : INN of investigational material : Nivolumab, Ipilimumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : Durvalumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Outcome(s)

Primary Outcome	efficacy
Secondary Outcome	efficacy safety

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria
Exclude criteria